DRKS00017617尚未招募不适用

Investigation of cytokinergicity and glycosylation Profile of IgE in chronic urticaria compared to allergy sufferers and healthy volunteers - ICY-GLYCU: (GLYCU (Investigating cytokinergicity and glykosilation profile of IgE in chronic urticaria)

Charité-Universitätsmedizin Berlin, Klinik für Dermatologie und Allergologie0 个研究点目标入组 90 人开始时间: 2019年11月5日最近更新: 2024年8月19日

适应症

试验速览

暂无简介。

•Healthy volunteers or Patients suffering from one of the following diseases:
•- Chronic urticaria
•- allergy sufferers (allergic rhinoconjunctivitis, allergic asthma)
•Furthermore:
•- Time of diagnosis of the disease > 3 months
•- For women of childbearing age: negative pregnancy test
•- Patients may have additional concomitant diseases, but only a dominant skin disease
•- No participation in other clinical trials 4 weeks before

•- Simultaneous/continuous treatment with immunosuppressants (e.g. cyclosporine, methotrexate, dapsone or others) within 4 weeks or 5 half-lives prior to study start, whichever is longer
•- Simultaneous/continuous treatment with omalizumab, dupilumab or other Biologics within 3 months before start of study
•- breast-feeding or pregnant women
•- Participation in another study with an investigational drug; participation less than 4 weeks or 5 half-lives of the investigational drug, whichever is longer
•- Persons who have concerns about compliance with the study procedure
•- Any disease which, in the opinion of the investigator, would impair participation in the study or put the person at risk
•- Persons who are officially or legally detained in a public facility
•- Taking leukotriene antagonists within 7 days of study initiation
•- History of drug abuse (drugs or alcohol) or other factors (e.g. severe psychiatric illness) that may limit the subjects' ability to participate in the study

发起方

Charité-Universitätsmedizin Berlin, Klinik für Dermatologie und Allergologie